Still’s disease is a serious orphan disease caused by a deregulation of the immune system triggering an acute inflammatory response. Under the auspices of UNIGE and HUG, an international team has successfully tested a molecule inhibitor of interleukin-18, a protein involved in immune response. These encouraging results in terms of safety and efficacy are paving the way for a new kind of treatment, not only for Still’s disease, but other rare inflammatory diseases, too.